还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

- p- G- r9 L4 e: I. x                               
登录/注册后可看大图

: U. D  S$ `0 J+ ~' N请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
) D$ V, }. V% {8 }1 d

Sub-category:
: r, X+ A# R; Q6 L4 E2 m$ bMolecular Targets

- s- [9 V7 y; j, ~
. }# J2 @  C- x7 x: k5 h) K7 H0 c6 `Category:
Tumor Biology

% x. c' i: U1 P; C8 q
$ m: t* z+ ]; [! M: qMeeting:
2011 ASCO Annual Meeting
7 I$ E' W" F) C4 T2 F( ^9 z
2 |4 |, s# J. F$ r( l$ o+ a$ j5 i
+ u5 m$ ^, E, F* q! o: OSession Type and Session Title:
4 X7 i+ p6 b4 nPoster Discussion Session, Tumor Biology
  i" T6 s1 A0 W. f4 \. h2 I

Abstract No:
10517

  Y4 Z4 Z, V# _' `" L8 D" H
Citation:
, y' _% }$ S" ]* ~/ lJ Clin Oncol 29: 2011 (suppl; abstr 10517)
& }9 l7 ~2 F% {( l5 _

( \* K# S5 L- {7 @Author(s):
* r$ V( y8 ?8 `# N* hJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
4 Z, p" M6 b- }


Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
1 g$ Z7 p, i: I. a- Z) m
, x3 f9 @  H/ o# RAbstract Disclosures

) f. D6 |$ V' N8 T+ vAbstract:
$ t/ `$ n0 L  p5 X0 T* {4 U

Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
/ R. E' r& Q9 Q" t6 ~: i
& ^* o2 A  \& z% @
5 l5 c% }& \" A5 W

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

3 F0 |* l0 U/ ~5 E) C/ U, a                               
登录/注册后可看大图

' h) `/ J5 E, X) V% x没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

8 ]# v2 y4 N3 n  M2 Z化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

/ x" Y/ @2 t+ {' \/ W" O+ P8 |  @                               
登录/注册后可看大图

+ n( x) J+ X( |1 ?  @易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
" `- S! R8 n! {ALK一个指标医院要900多 ...

  v' h& q. B6 X  c# T; z平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊